The Lustgarten Foundation announces two new pancreatic cancer research laboratories through respective partnerships with Dana-Farber Cancer Institute and Massachusetts Institute of Technology (MIT).
Brigitte Régnier found a treatment team that was using an unusual approach of giving chemoradiation before surgery for pancreatic cancer.
An international team of researchers led by Dr. David Tuveson has found that organoids can predict how pancreatic cancer patients will respond to different treatments.
The Foundation’s dedicated lab at Cold Spring Harbor Laboratory (CSHL) used organoid technology to find that pancreatic cancer cells reprogram…
With a median survival of only 6 months and a 5-year survival rate of about 8%, patients tend to be…
Dr. Stillman has served as director of the Laboratory’s National Cancer Institute (NCI)-designated Cancer Center for 25 years, shepherding the…
A woman’s treatment for non-operable pancreatic cancer at Memorial Sloan Kettering includes FOLFIRINOX and stereotactic body radiation therapy.
New research finds that reducing antioxidants can help kill pancreatic cancer cells, suggesting a new direction for treatment.
